Casey M Rebholz1, Brad C Astor2, Morgan E Grams3, Marc K Halushka4, Mariana Lazo5, Ron C Hoogeveen6, Christie M Ballantyne6, Josef Coresh5, Elizabeth Selvin5. 1. Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 2. Departments of Medicine and Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 3. Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA Division of Nephrology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA. 4. Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 5. Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA Division of General Internal Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA. 6. Department of Medicine, Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.
Abstract
BACKGROUND: Advanced glycation end products and their cell-bound receptors are thought to mediate the adverse effects of vascular disease through oxidative stress, inflammation and endothelial dysfunction. We examined the association between the soluble form of receptor for advanced glycation end products (sRAGE) and kidney disease. METHODS: In this case-cohort study nested within the Atherosclerosis Risk in Communities (ARIC) study, baseline sRAGE levels were measured in a cohort random sample of participants without kidney disease (n= 1218), and among participants who developed incident chronic kidney disease (CKD) [estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m(2) and ≥25% eGFR decline, n = 151] and end-stage renal disease (ESRD) [entry in the US Renal Data System (USRDS) registry, n = 152]. RESULTS:Baseline sRAGE levels were inversely related to baseline eGFR (r = -0.13). After adjusting for age, sex and race, one interquartile range higher log10-transformed sRAGE was associated with development of CKD [odds ratio: 1.39; 95% confidence interval (95% CI) 1.06-1.83; P = 0.02] and ESRD (hazard ratio: 1.97; 95% CI 1.47-2.64; P < 0.001). These associations were not significant after eGFR adjustment. CONCLUSIONS: High sRAGE levels are associated with incident CKD and ESRD risk, but not after adjustment for kidney function at baseline. Future studies are needed to investigate specific mechanisms underlying the association of sRAGE with kidney disease risk.
RCT Entities:
BACKGROUND: Advanced glycation end products and their cell-bound receptors are thought to mediate the adverse effects of vascular disease through oxidative stress, inflammation and endothelial dysfunction. We examined the association between the soluble form of receptor for advanced glycation end products (sRAGE) and kidney disease. METHODS: In this case-cohort study nested within the Atherosclerosis Risk in Communities (ARIC) study, baseline sRAGE levels were measured in a cohort random sample of participants without kidney disease (n= 1218), and among participants who developed incident chronic kidney disease (CKD) [estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m(2) and ≥25% eGFR decline, n = 151] and end-stage renal disease (ESRD) [entry in the US Renal Data System (USRDS) registry, n = 152]. RESULTS: Baseline sRAGE levels were inversely related to baseline eGFR (r = -0.13). After adjusting for age, sex and race, one interquartile range higher log10-transformed sRAGE was associated with development of CKD [odds ratio: 1.39; 95% confidence interval (95% CI) 1.06-1.83; P = 0.02] and ESRD (hazard ratio: 1.97; 95% CI 1.47-2.64; P < 0.001). These associations were not significant after eGFR adjustment. CONCLUSIONS: High sRAGE levels are associated with incident CKD and ESRD risk, but not after adjustment for kidney function at baseline. Future studies are needed to investigate specific mechanisms underlying the association of sRAGE with kidney disease risk.
Authors: Christin Wittwer; Julia Lehner; Debora Fersching; Barbara Siegele; Oliver J Stoetzer; Stefan Holdenrieder Journal: Anticancer Res Date: 2012-05 Impact factor: 2.480
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: M P Wautier; O Chappey; S Corda; D M Stern; A M Schmidt; J L Wautier Journal: Am J Physiol Endocrinol Metab Date: 2001-05 Impact factor: 4.310
Authors: Julie K Bower; James S Pankow; Mariana Lazo; Eric Christenson; Ron C Hoogeveen; Christie M Ballantyne; Marc K Halushka; Brad C Astor; Elizabeth Selvin Journal: Clin Biochem Date: 2013-11-15 Impact factor: 3.281
Authors: Elizabeth Selvin; Marc K Halushka; Andreea M Rawlings; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh; Brad C Astor Journal: Diabetes Date: 2013-02-08 Impact factor: 9.461
Authors: Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier Journal: J Am Soc Nephrol Date: 2015-08-26 Impact factor: 10.121
Authors: Stephanie J Loomis; Yuan Chen; David B Sacks; Eric S Christenson; Robert H Christenson; Casey M Rebholz; Elizabeth Selvin Journal: Clin Chem Date: 2017-03-09 Impact factor: 8.327
Authors: Mahmoud Al Rifai; Andrea L C Schneider; Alvaro Alonso; Nisa Maruthur; Christina M Parrinello; Brad C Astor; Ron C Hoogeveen; Elsayed Z Soliman; Lin Y Chen; Christie M Ballantyne; Marc K Halushka; Elizabeth Selvin Journal: J Diabetes Complications Date: 2014-11-25 Impact factor: 2.852
Authors: Andreas Leiherer; Axel Muendlein; Philipp Rein; Christoph H Saely; Elena Kinz; Alexander Vonbank; Peter Fraunberger; Heinz Drexel Journal: PLoS One Date: 2014-12-05 Impact factor: 3.240
Authors: Rafał Rzepka; Barbara Dołegowska; Aleksandra Rajewska; Sebastian Kwiatkowski; Daria Sałata; Marta Budkowska; Leszek Domański; Wioletta Mikołajek-Bedner; Andrzej Torbé Journal: Biomed Res Int Date: 2015-08-27 Impact factor: 3.411
Authors: Ligia Maria Claro; Andrea N Moreno-Amaral; Ana Carolina Gadotti; Carla J Dolenga; Lia S Nakao; Marina L V Azevedo; Lucia de Noronha; Marcia Olandoski; Thyago P de Moraes; Andréa E M Stinghen; Roberto Pécoits-Filho Journal: Toxins (Basel) Date: 2018-09-23 Impact factor: 4.546